Altimmune (ALT) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

ALT Altimmune

Watchlist

6.860
-0.180-2.56%

Close Oct 16 16:00 ET

6.761
-0.099-1.45%

Post 20:01 ET

487.55MMarket Cap-4208P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Millennium Management LLC Increases Stake in Altimmune Inc
Yahoo Finance19:02 ET
Altimmune Call Volume Above Normal and Directionally Bullish
TipRanksOct 15 15:30 ET
Altimmune to Present New Data on the Lipidomic Profile in Subjects Treated With Pemvidutide at The Liver Meeting 2024
Yahoo FinanceOct 15 08:00 ET
Novo Nordisk, Eli Lilly Could Face Downward Pressure Despite Market Dominance From Potentially 16 New Obesity Drugs: See The Names
BenzingaOct 11 14:11 ET
Altimmune Inc (ALT) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges
InvestingOct 9 11:35 ET
Analysts Are Bullish on Top Healthcare Stocks: Altimmune (ALT), Hansa Biopharma AB (SE:HNSA)
TipRanksOct 9 05:01 ET · Ratings

Comments

Clembot82

Sep 30 12:54

Wish I had some dry powder

$Altimmune (ALT.US)$ Money tied up on some other plays, well see how long is at these levels. There are always more opportunities to come. 🐂 📈

frogoracletrading

Sep 21 12:45

$ALT Support / Resistance Levels

Watching for consolidation over the 7.40 top of the POC to setup a push to 10.00+
Larger Image: tradingview.com...
$Altimmune (ALT.US)$

Trytosaveabit

Sep 10 06:56

Update

$Altimmune (ALT.US)$ Altimmune Presents Data From Its Phase 2, MRI-Based Body Composition Sub-study Of Pemvidutide In Subjects With Overweight And Obesity
Benzinga· 1 min ago
In an MRI sub-study of 67 subjects from the Phase 2 MOMENTUM obesity trial, 50 of whom were treated with pemvidutide for 48 weeks, the lean loss ratio, defined as the change in lean mass compared to the change in total mass, was 21.9%.
Lean mass preservation was greater in subjects aged 60 years and older, in whom the ...

Jaguar8

Sep 10 06:46

NEWS

$Altimmune (ALT.US)$
Altimmune Presents Results of a Phase 2 MRI-Based Body Composition Sub-Study at 60th Annual Meeting of the European Association for the Study of Diabetes
Altimmune presented results from a Phase 2 MRI-based body composition sub-study of pemvidutide at the 60th Annual Meeting of the European Association for the Study of Diabetes. The study, involving 67 subjects from the MOMENTUM obesity trial, showed promising outcomes for pemvidutide, a novel GLP-1/glucagon dual receptor...